Evidence map›Paper›PMID 41858318›Full record

ReviewKidney international reports2026

Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.

Abigail J Berube, Eryn Yu, Pukhraj S Gaheer, Matthew B Lanktree

Abstract readReview
In one paragraph

Review in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abigail J BerubeDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Eryn YuDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pukhraj S GaheerDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Matthew B LanktreeDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mendelian randomization leverages the random assortment of alleles at conception to investigate how genetically mediated changes in an exposure affect an outcome while minimizing concerns related to reverse causation and unmeasured confounding. Initially applied to assess the causal impact of modifiable traditional risk factors as mediators of disease risk, Mendelian randomization studies now incorporate large-scale multiomic datasets providing valuable insights for drug target discovery. By analyzing

Indexed as

drug targetsgenomicsMendelian randomizationmultiomicsnephrologytherapeutic discovery

Identifiers

PMID41858318
PMCPMC12997310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.